Last reviewed · How we verify
BEP(500)
BEP(500) is a bispecific antibody that simultaneously engages two distinct molecular targets to enhance anti-tumor immune responses.
BEP(500) is a bispecific antibody that simultaneously engages two distinct molecular targets to enhance anti-tumor immune responses. Used for Solid tumors (specific indication under investigation in phase 3).
At a glance
| Generic name | BEP(500) |
|---|---|
| Sponsor | Institute of Cancer Research, United Kingdom |
| Drug class | Bispecific antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a bispecific antibody developed by the Institute of Cancer Research, BEP(500) is designed to bridge immune effector cells with tumor cells or modulate key signaling pathways involved in cancer progression. The exact dual targets and mechanism remain proprietary, but bispecific approaches in oncology typically aim to enhance T-cell activation, redirect immune cells to tumors, or block immunosuppressive pathways.
Approved indications
- Solid tumors (specific indication under investigation in phase 3)
Common side effects
Key clinical trials
- Micronutrient Dose Response Study in Bangladesh (NA)
- Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors (NA)
- Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours (PHASE3)
- Nutritional Support and Prophylaxis Doses of Azithromycin for Pregnant Women - Mumta Pregnant Women Trial (NA)
- Effect of a Fortified Balanced Energy-Protein Supplement on Birth Outcome and Child Growth in Houndé District, Burkina Faso. (PHASE4)
- Enhancing Nutrition and Antenatal Infection Treatment for Maternal and Child Health in Ethiopia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BEP(500) CI brief — competitive landscape report
- BEP(500) updates RSS · CI watch RSS
- Institute of Cancer Research, United Kingdom portfolio CI